PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
475.28%
Revenue growth above 1.5x PUK's 27.93%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
475.28%
Gross profit growth above 1.5x PUK's 27.93%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-361.30%
Negative EBIT growth while PUK is at 246.79%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-361.30%
Negative operating income growth while PUK is at 27.93%. Joel Greenblatt would press for urgent turnaround measures.
26.57%
Net income growth under 50% of PUK's 2157.71%. Michael Burry would suspect the firm is falling well behind a key competitor.
-100.00%
Negative EPS growth while PUK is at 1749.71%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-100.00%
Negative diluted EPS growth while PUK is at 1749.71%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-100.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-100.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.